Metallo-beta-lactamases: mechanisms, treatment challenges, and future prospects

References

• Thakuria B. The Beta Lactam Antibiotics as an Empirical Therapy in a Developing Country: An Update on Their Current Status and Recommendations to Counter the Resistance against Them. JCDR. 2013. doi: 10.7860/JCDR/2013/5239.3052
   Google Scholar
• Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi:10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• Dadgostar P. Antimicrobial Resistance: Implications and Costs. Infect Drug Resist. 2019;12:3903–3910. doi:10.2147/IDR.S234610
   PubMed Web of Science ®Google Scholar
• WHO. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. [cited 2023 Sep 26] Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
   Google Scholar
• WHO. 2021. Global research agenda for antimicrobial resistance in human health. [cited 2023 Sep 26]. Available from: https://www.who.int/publications/m/item/global-research-agenda-for-antimicrobial-resistance-in-human-health
   Google Scholar
• De Angelis G, Del Giacomo P, Posteraro B, et al. Molecular mechanisms, epidemiology, and clinical importance of β-lactam resistance in Enterobacteriaceae. Int J Mol Sci. 2020;21(14):5090. doi: 10.3390/ijms21145090
   PubMed Web of Science ®Google Scholar
• Mojica MF, Rossi MA, Vila AJ, et al. The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 2022;22(1):e28–e34.
   PubMed Web of Science ®Google Scholar
• Diene SM, Pontarotti P, Azza S, et al. Origin, diversity, and multiple roles of enzymes with metallo-β-lactamase Fold from different organisms. Cells. 2023;12(13):1752. doi: 10.3390/cells12131752
   PubMed Web of Science ®Google Scholar
• Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321–331.
   PubMed Web of Science ®Google Scholar
• Sheu CC, Chang YT, Lin SY, et al. Infections caused by Carbapenem-Resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80. doi:10.3389/fmicb.2019.00080
   PubMed Web of Science ®Google Scholar
• Bahr G, Gonzalez LJ, Vila AJ. Metallo-beta-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design. Chem Rev. 2021;121(13):7957–8094. doi:10.1021/acs.chemrev.1c00138
   PubMed Web of Science ®Google Scholar
• Mojica MF, Bonomo RA, Fast W. B1-metallo-beta-lactamases: where do we stand? Curr Drug Targets. 2016;17(9):1029–1050. doi:10.2174/1389450116666151001105622
   PubMed Web of Science ®Google Scholar
• Wang Z, Fast W, Valentine AM, et al. Metallo-beta-lactamase: structure and mechanism. Curr Opin Chem Biol. 1999;3(5):614–622. doi:10.1016/S1367-5931(99)00017-4
   PubMed Web of Science ®Google Scholar
• Arer V, Kar D. Biochemical exploration of beta-lactamase inhibitors. Front Genet. 2022;13:1060736. doi:10.3389/fgene.2022.1060736
   PubMed Web of Science ®Google Scholar
• Kanj SS, Bassetti M, Kiratisin P, et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2022;60(3):106633. doi: 10.1016/j.ijantimicag.2022.106633
   PubMed Web of Science ®Google Scholar
• Vazquez-Ucha JC, Arca-Suarez J, Bou G, et al. New carbapenemase inhibitors: clearing the way for the β-Lactams. Int J Mol Sci. 2020;21(23):9308. doi: 10.3390/ijms21239308
   PubMed Web of Science ®Google Scholar
• de Sousa Coelho F, Mainardi JL. The multiple benefits of second-generation beta-lactamase inhibitors in treatment of multidrug-resistant bacteria. Infect Dis Now. 2021;51(6):510–517. doi:10.1016/j.idnow.2020.11.007
   PubMedGoogle Scholar
• Boyd SE, Livermore DM, Hooper DC, et al. Metallo-beta-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64(10). doi: 10.1128/AAC.00397-20
   Web of Science ®Google Scholar
• Tang B, Yang A, Liu P, et al. Outer membrane vesicles transmitting bla(NDM-1) mediate the emergence of carbapenem-resistant hypervirulent Klebsiella pneumoniae. Antimicrob Agents Chemother. 2023;67(5):e0144422. doi: 10.1128/aac.01444-22
   PubMed Web of Science ®Google Scholar
• Watanabe M, Iyobe S, Inoue M, et al. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991;35(1):147–151. doi:10.1128/AAC.35.1.147
   PubMed Web of Science ®Google Scholar
• Pongchaikul P, Mongkolsuk P. Comprehensive Analysis of Imipenemase (IMP)-type metallo-β-lactamase: a global distribution threatening asia. Antibiotics. 2022;11(2):236. doi: 10.3390/antibiotics11020236
   Google Scholar
• Beta-lactamase Database. 2024. [cited 2024 Jan 15]. Available from: http://bldb.eu/BLDB.php?prot=B1#IMP
   Google Scholar
• Bush K, Bradford PA. Epidemiology of beta-lactamase-producing pathogens. Clin Microbiol Rev. 2020;33(2). doi: 10.1128/CMR.00047-19
   PubMed Web of Science ®Google Scholar
• Lauretti L, Riccio ML, Mazzariol A, et al. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother. 1999;43(7):1584–1590. doi: 10.1128/AAC.43.7.1584
   PubMed Web of Science ®Google Scholar
• Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece–a review of the current evidence. Euro Surveill. 2008;13(4):7–8. doi: 10.2807/ese.13.04.08023-en
   Google Scholar
• Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, et al. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. J Antimicrob Chemother. 2019;74(7):2051–2054. doi: 10.1093/jac/dkz125
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Rabine S, Hackel M, et al. Multiyear, multinational survey of the incidence and global distribution of metallo-beta-lactamase-producing enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(2):1067–1078. doi: 10.1128/AAC.02379-15
   PubMed Web of Science ®Google Scholar
• Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046–5054. doi: 10.1128/AAC.00774-09
   PubMed Web of Science ®Google Scholar
• Zowawi HM, Sartor AL, Balkhy HH, et al. Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf cooperation council: dominance of OXA-48 and NDM producers. Antimicrob Agents Chemother. 2014;58(6):3085–3090. doi: 10.1128/AAC.02050-13
   PubMed Web of Science ®Google Scholar
• Ma J, Song X, Li M, et al. Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res. 2023;266:127249. doi: 10.1016/j.micres.2022.127249
   PubMedGoogle Scholar
• CDC. 2022. COVID-19 U.S. impact on antimicrobial resistance. [cited 2023 Sep 26]. Available from: https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf
   Google Scholar
• Porretta AD, Baggiani A, Arzilli G, et al. Increased risk of acquisition of New Delhi metallo-beta-lactamase-producing carbapenem-resistant enterobacterales (NDM-CRE) among a cohort of COVID-19 patients in a teaching hospital in Tuscany, Italy. Pathogens. 2020;9(8):635. doi: 10.3390/pathogens9080635
   PubMed Web of Science ®Google Scholar
• Caliskan-Aydogan O, Alocilja EC. A review of Carbapenem Resistance in Enterobacterales and its detection techniques. Microorganisms. 2023;11(6):1491. doi: 10.3390/microorganisms11061491
   PubMed Web of Science ®Google Scholar
• Hu Y, Matsui Y, WR L. Risk factors for fecal carriage of drug-resistant Escherichia coli: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):31. doi:10.1186/s13756-020-0691-3
   PubMed Web of Science ®Google Scholar
• Wailan AM, Paterson DL. The spread and acquisition of NDM-1: a multifactorial problem. Expert Rev Anti Infect Ther. 2014;12(1):91–115.
   PubMed Web of Science ®Google Scholar
• Ahammad ZS, Sreekrishnan TR, Hands CL, et al. Increased waterborne blaNDM-1 resistance gene abundances associated with seasonal human pilgrimages to the upper ganges river. Environ Sci Technol. 2014;48(5):3014–3020. doi:10.1021/es405348h
   PubMed Web of Science ®Google Scholar
• WHO. 2023. One health. [cited 2023 Sep 26]. Available from: https://www.who.int/health-topics/one-health#tab=tab_1
   Google Scholar
• Mushtaq S, Vickers A, Doumith M, et al. Activity of beta-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2021;76(1):160–170. doi:10.1093/jac/dkaa391
   PubMed Web of Science ®Google Scholar
• Tsivkovski R, Totrov M, Lomovskaya O. Biochemical characterization of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases. Antimicrob Agents Chemother. 2020;64(6). doi: 10.1128/AAC.00130-20
   Web of Science ®Google Scholar
• Ghazi IM, Crandon JL, Lesho EP, et al. Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against enterobacteriaceae isolates producing Verona integron-encoded metallo-beta-lactamase (VIM) in a murine thigh infection model. Antimicrob Agents Chemother. 2015;59(11):7145–7147. doi:10.1128/AAC.00794-15
   PubMed Web of Science ®Google Scholar
• MacVane SH, Crandon JL, Nichols WW, et al. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-beta-lactamase-producing enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2014;58(11):7007–7009. doi:10.1128/AAC.02662-14
   PubMed Web of Science ®Google Scholar
• Walsh TR, Toleman MA, Poirel L, et al. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18(2):306–325. doi:10.1128/CMR.18.2.306-325.2005
   PubMed Web of Science ®Google Scholar
• Zhao S, Kennedy S, Perry MR, et al. Epidemiology of and risk factors for mortality due to carbapenemase-producing organisms (CPO) in healthcare facilities. J Hosp Infect. 2021;110:184–193. doi: 10.1016/j.jhin.2021.01.028
   PubMed Web of Science ®Google Scholar
• Matar GM. Editorial: Pseudomonas and acinetobacter: from drug resistance to pathogenesis. Front Cell Infect Microbiol. 2018;8:68. doi:10.3389/fcimb.2018.00068
   PubMed Web of Science ®Google Scholar
• Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–423. doi: 10.1111/1469-0691.12363
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Barth AL, Goncalves AL, et al. The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother. 2006;58(2):387–392. doi: 10.1093/jac/dkl239
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of carbapenem-resistant enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2). doi: 10.1128/AAC.01882-17
   Web of Science ®Google Scholar
• Falcone M, Tiseo G, Carbonara S, et al. Mortality attributable to bloodstream infections caused by different carbapenem-resistant gram-negative bacilli: results from a nationwide study in Italy (ALARICO network). Clin Infect Dis. 2023;76(12):2059–2069. doi: 10.1093/cid/ciad100
   PubMed Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-3
   PubMed Web of Science ®Google Scholar
• Boutzoukas AE, Komarow L, Chen L, et al. International epidemiology of carbapenemase-producing Escherichia coli. Clin Infect Dis. 2023;77(4):499–509. doi: 10.1093/cid/ciad288
   PubMed Web of Science ®Google Scholar
• CLSI Outreach Working Group. 2016. Laboratory detection and reporting of carbapenem-resistant enterobacteriaceae (CRE). [cited Sep 26]. Available from: https://clsi.org/media/1720/script-orwg-cre-laboratory-role.pdf
   Google Scholar
• EUCAST. 2017. EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. [cited 2023 Sep 26]. Available from: https://www.eucast.org/resistance_mechanisms
   Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 Guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023. doi: 10.1093/cid/ciad428
   Google Scholar
• Tamma PD, Simner PJ, Kraft CS. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J Clin Microbiol. 2018;56(11). doi: 10.1128/JCM.01140-18
   Web of Science ®Google Scholar
• Amjad A, Mirza I, Abbasi S, et al. Modified Hodge test: a simple and effective test for detection of carbapenemase production. Iran J Microbiol. 2011;3(4):189–193.
   PubMedGoogle Scholar
• Ghebremedhin B, Halstenbach A, Smiljanic M, et al. MALDI-TOF MS based carbapenemase detection from culture isolates and from positive blood culture vials. Ann Clin Microbiol Antimicrob. 2016;15(5). doi: 10.1186/s12941-016-0120-x
   PubMedGoogle Scholar
• Lahiri S, Venkataraman R, Jagan A, et al. Evaluation of LAMP-based assays for carbapenemase genes. J Med Microbiol. 2019;68(10):1431–1437. doi: 10.1099/jmm.0.001050
   PubMed Web of Science ®Google Scholar
• Motro Y, Moran-Gilad J. Next-generation sequencing applications in clinical bacteriology. Biomol Detect Quantif. 2017;14:1–6. doi:10.1016/j.bdq.2017.10.002
   PubMedGoogle Scholar
• Su M, Satola SW, Read TD, et al. Genome-based prediction of bacterial antibiotic resistance. J Clin Microbiol. 2019;57(3). doi: 10.1128/JCM.01405-18
   Web of Science ®Google Scholar
• Nordmann P, Sadek M, Demord A, et al. NitroSpeed-carba NP test for rapid detection and differentiation between different classes of carbapenemases in Enterobacterales. J Clin Microbiol. 2020;58(9). doi: 10.1128/JCM.00932-20
   Web of Science ®Google Scholar
• Dortet L, Poirel L, Errera C, et al. CarbAcineto NP test for rapid detection of carbapenemase-producing acinetobacter spp. J Clin Microbiol. 2014;52(7):2359–2364. doi:10.1128/JCM.00594-14
   PubMed Web of Science ®Google Scholar
• Uechi K, Tada T, Shimada K, et al. A modified carbapenem inactivation method, CIMTris, for carbapenemase production in acinetobacter and pseudomonas species. J Clin Microbiol. 2017;55(12):3405–3410. doi: 10.1128/JCM.00893-17
   PubMed Web of Science ®Google Scholar
• Pasteran F, Gonzalez LJ, Albornoz E, et al. Triton hodge test: improved protocol for modified hodge test for enhanced detection of NDM and other carbapenemase producers. J Clin Microbiol. 2016;54(3):640–649. doi:10.1128/JCM.01298-15
   PubMed Web of Science ®Google Scholar
• Garcia-Fernandez S, Morosini MI, Marco F, et al. Evaluation of the eazyplex(R) SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals. J Antimicrob Chemother. 2015;70(4):1047–1050. doi: 10.1093/jac/dku476
   PubMed Web of Science ®Google Scholar
• Cuzon G, Naas T, Bogaerts P, et al. Evaluation of a DNA microarray for the rapid detection of extended-spectrum beta-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother. 2012;67(8):1865–1869. doi:10.1093/jac/dks156
   PubMed Web of Science ®Google Scholar
• Prat C, Lacoma A. Bacteria in the respiratory tract-how to treat? Or do not treat? Int J Infect Dis. 2016;51:113–122. doi:10.1016/j.ijid.2016.09.005
   PubMed Web of Science ®Google Scholar
• Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of Asymptomatic Bacteriuria: 2019 update by the infectious diseases society of America. Clin Infect Dis. 2019;68(10):e83–e110. doi: 10.1093/cid/ciz021
   PubMed Web of Science ®Google Scholar
• Zakhour J, Haddad SF, Kerbage A, et al. Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance. Int J Antimicrob Agents. 2023;62(1):106816. doi: 10.1016/j.ijantimicag.2023.106816
   PubMed Web of Science ®Google Scholar
• Mitchell BG, Fasugba O, Gardner A, et al. Reducing catheter-associated urinary tract infections in hospitals: study protocol for a multi-site randomised controlled study. BMJ Open. 2017;7(11):e018871. doi: 10.1136/bmjopen-2017-018871
   PubMed Web of Science ®Google Scholar
• Kenaa B, Richert ME, Claeys KC, et al. Ventilator-associated pneumonia: diagnostic test stewardship and relevance of culturing practices. Curr Infect Dis Rep. 2019;21(12):50. doi: 10.1007/s11908-019-0708-3
   PubMed Web of Science ®Google Scholar
• Tamma PD, Bergman Y, Jacobs EB, et al. Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates. Infect Control Hosp Epidemiol. 2023;44(5):762–767. doi: 10.1017/ice.2022.161
   PubMed Web of Science ®Google Scholar
• Agarwal A, Srivastava J, Maheshwari U, et al. Molecular characterization and antimicrobial susceptibility profile of New Delhi metallo-beta-lactamase-1-producing Escherichia coli among hospitalized patients. J Lab Physicians. 2018;10(2):149–154. doi:10.4103/JLP.JLP_76_17
   PubMedGoogle Scholar
• Fomda BA, Khan A, Zahoor D. NDM-1 (New Delhi metallo beta lactamase-1) producing Gram-negative bacilli: emergence & clinical implications. Indian J Med Res. 2014;140(5):672–678.
   PubMedGoogle Scholar
• Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602. doi: 10.1016/S1473-3099(10)70143-2
   PubMed Web of Science ®Google Scholar
• Mataseje LF, Abdesselam K, Vachon J, et al. Results from the Canadian nosocomial infection surveillance program on carbapenemase-producing Enterobacteriaceae, 2010 to 2014. Antimicrob Agents Chemother. 2016;60(11):6787–6794. doi: 10.1128/AAC.01359-16
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Poirel L, et al. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542–544. doi:10.1093/jac/dkx393
   PubMed Web of Science ®Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus Aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing enterobacterales. Clin Infect Dis. 2021;72(11):1871–1878. doi: 10.1093/cid/ciaa586
   PubMed Web of Science ®Google Scholar
• Mauri C, Maraolo AE, Di Bella S, et al. The revival of Aztreonam in combination with avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: a systematic review of in vitro studies and clinical cases. Antibiotics. 2021;10(8):1012. doi: 10.3390/antibiotics10081012
   Google Scholar
• Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection. 2020;48(6):835–851. doi:10.1007/s15010-020-01520-6
   PubMed Web of Science ®Google Scholar
• Timsit JF, Paul M, Shields RK, et al. Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies. Clin Infect Dis. 2022;75(6):1081–1084. doi: 10.1093/cid/ciac078
   PubMed Web of Science ®Google Scholar
• CDC. 2023. Outbreak of extensively drug-resistant Pseudomonas aeruginosa associated with artificial tears. [cited 2023 Sep 26]. Available from: https://www.cdc.gov/hai/outbreaks/crpa-artificial-tears.html
   Google Scholar
• Tiseo G, Suardi LR, Leonildi A, et al. Meropenem/Vaborbactam plus aztreonam for the treatment of New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae infections. J Antimicrob Chemother. 2023;78(9):2377–2379. doi:10.1093/jac/dkad206
   PubMed Web of Science ®Google Scholar
• Maraki S, Mavromanolaki VE, Moraitis P, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-beta-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755–1759. doi: 10.1007/s10096-021-04197-3
   PubMed Web of Science ®Google Scholar
• Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2022;41(7):1003–1022. doi: 10.1007/s10096-020-04121-1
   PubMed Web of Science ®Google Scholar
• Morrissey I, Olesky M, Hawser S, et al. In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020;64(3). doi: 10.1128/AAC.01699-19
   Web of Science ®Google Scholar
• Ni W, Han Y, Liu J, et al. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016;95(11):e3126. doi: 10.1097/MD.0000000000003126
   PubMed Web of Science ®Google Scholar
• Pogue JM, Neelakanta A, Mynatt RP, et al. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the detroit medical center. Clin Infect Dis. 2014;59(Suppl 6):S388–393. doi:10.1093/cid/ciu594
   PubMed Web of Science ®Google Scholar
• Wang J, Shah BK, Zhao J, et al. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. BMC Infect Dis. 2023;23(1):351. doi:10.1186/s12879-023-08339-0
   PubMed Web of Science ®Google Scholar
• Ruedas-Lopez A, Alonso-Garcia I, Lasarte-Monterrubio C, et al. Selection of AmpC beta-Lactamase Variants and Metallo-beta-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother. 2022;66(2):e0206721. doi: 10.1128/aac.02067-21
   PubMed Web of Science ®Google Scholar
• Voor in ‘t Holt, A. F, Severin, J. A. Hagenaars MBH, et al. VIM-positive Pseudomonas aeruginosa in a large tertiary care hospital: matched case-control studies and a network analysis. Antimicrob Resist Infect Control. 2018;7(1):32. doi: 10.1186/s13756-018-0325-1
   PubMedGoogle Scholar
• Haddad SF, Allaw F, Kanj SS. Duration of antibiotic therapy in Gram-negative infections with a particular focus on multidrug-resistant pathogens. Curr Opin Infect Dis. 2022;35(6):614–620. doi:10.1097/QCO.0000000000000861
   PubMed Web of Science ®Google Scholar
• Sanders NH, Hannibal T. An outbreak of New Delhi metallo-beta-lactamase among intensive care unit patients in an acute care hospital. American Journal Of Infection Control. 2022;50(7):S27–S28. doi: 10.1016/j.ajic.2022.03.038
   Google Scholar
• Koo VS, O’Neill P, Elves A. Multidrug-resistant NDM-1 Klebsiella outbreak and infection control in endoscopic urology. BJU Int. 2012;110(11 Pt C):E922–926. doi:10.1111/j.1464-410X.2012.11556.x
   PubMedGoogle Scholar
• Bruins MJ, Ter Heege AH K, van den Bos-KromhoutMI, et al. VIM-carbapenemase-producing Escherichia coli in a residential care home in the Netherlands. J Hosp Infect. 2020;104(1):20–26. doi:10.1016/j.jhin.2019.08.012
   PubMed Web of Science ®Google Scholar
• Tischendorf J, de Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant enterobactericeae: a systematic review. Am J Infect Control. 2016;44(5):539–543. doi:10.1016/j.ajic.2015.12.005
   PubMed Web of Science ®Google Scholar
• Richter SS, Marchaim D. Screening for carbapenem-resistant enterobacteriaceae: who, when, and how? Virulence. 2017;8(4):417–426. doi:10.1080/21505594.2016.1255381
   PubMed Web of Science ®Google Scholar
• Pirzadian J, Voor in ‘t Holt AF, Hossain M, et al. Limiting spread of VIM-positive Pseudomonas aeruginosa from colonized sink drains in a tertiary care hospital: a before-and-after study. PloS One. 2023;18(3):e0282090. doi: 10.1371/journal.pone.0282090
   PubMed Web of Science ®Google Scholar
• Liu B, Trout REL, Chu GH, et al. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-beta-lactamase inhibitor for carbapenem-resistant bacterial infections. J Med Chem. 2020;63(6):2789–2801. doi: 10.1021/acs.jmedchem.9b01518
   PubMed Web of Science ®Google Scholar
• Hecker SJ, Reddy KR, Lomovskaya O, et al. Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo-beta-lactamases. J Med Chem. 2020;63(14):7491–7507. doi: 10.1021/acs.jmedchem.9b01976
   PubMed Web of Science ®Google Scholar
• Khairnar K, Raut MP, Chandekar RH, et al. Novel bacteriophage therapy for controlling metallo-beta-lactamase producing Pseudomonas aeruginosa infection in catfish. BMC Vet Res. 2013;9(1):264. doi: 10.1186/1746-6148-9-264
   PubMedGoogle Scholar